TB-500
Tissue and Repair Signalling
£28.00per vial
Awaiting batch
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
TB-500 cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
TB-500 is a research peptide listed in the UK for in-vitro laboratory use only. It is not a medicine and it is not for human or veterinary use. This page is the TB-500 listing for Protocol Peptides UK.
TB-500 is a synthetic peptide based on the actin-binding region of thymosin beta-4, a protein involved in actin sequestration, cell migration, and angiogenesis. Laboratory work examines it in wound-repair, tendon and ligament, corneal, and neovascularisation models, with emphasis on cytoskeletal reorganisation.
Also known as Thymosin beta-4 fragment, Ac-LKKTETQ.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
- UK DISPATCH
- TRACKED SHIPPING
- COA ON RELEASE
- SECURE PAYMENT
Compound details
TB-500 is a synthetic peptide based on the actin-binding region of thymosin beta-4, a protein involved in actin sequestration, cell migration, and angiogenesis. Laboratory work examines it in wound-repair, tendon and ligament, corneal, and neovascularisation models, with emphasis on cytoskeletal reorganisation.
TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin beta-4, the LKKTETQ motif, acetylated at the N-terminus. Thymosin beta-4 is the principal G-actin sequestering protein in mammalian cells, and the fragment is studied for the same actin-binding behaviour in isolation. Its mechanism is described in the literature as receptor-independent, which distinguishes it structurally from the receptor-agonist compounds catalogued elsewhere in this reference.
- Molecular weight
- 889 g/mol
- Sequence
- Ac-LKKTETQ-OH
- Presentation
- Sealed 3ml vial
Molecular weight source: PubChem CID 62707662, N-acetyl LKKTETQ. View the PubChem record
TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin beta-4, the LKKTETQ motif, acetylated at the N-terminus. Thymosin beta-4 is the principal G-actin sequestering protein in mammalian cells, and the fragment is studied for the same actin-binding behaviour in isolation. Its mechanism is described in the literature as receptor-independent, which distinguishes it structurally from the receptor-agonist compounds catalogued elsewhere in this reference.
Preclinical investigations have examined TB-500 in actin polymerisation assays, endothelial cell migration models, and angiogenesis frameworks. Published work also references its influence on inflammatory signalling and on cellular differentiation processes under controlled conditions. Research contexts include tendon and ligament repair models, corneal and dermal wound models, and cardiac tissue remodelling models.
TB-500 is catalogued here as a reference compound for laboratory research. The findings above are drawn from animal and cell-culture studies. No therapeutic, diagnostic, or clinical conclusion is drawn from them, and none should be inferred.
TB-500 is listed in a sealed 3ml vial, at 5mg and 10mg.
When a batch is released, it is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry, which for this compound also separates the acetylated seven-residue fragment from the full 43-residue parent protein that shares its name in common usage. Those are the two analytical methods used, and no other method is claimed.
When a batch is released, the batch number on the vial resolves to the public Certificate of Analysis for that batch, reporting the compound, the lot reference, the HPLC result, the mass-spectrometry result, the analysis date. The document is published before the batch enters the catalogue. Specimen documents on this site are for demonstration only and are not genuine laboratory reports.
When a batch is released, it is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
TB-500
TB5602Specimen record. Not a genuine laboratory report.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 97.9% |
| Identity | Mass spectrometry | Consistent with expected mass |
HPLC
Purity by chromatography
ON RELEASE
MASS SPECTROMETRY
Identity confirmation
ON RELEASE
PUBLIC COA
Each released batch number resolves to its Certificate of Analysis
COMMITTED
Research Use Only
TB-500 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about TB-500. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
When analytical results are published for TB-500, they relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch. Specimen documents are for demonstration only and are not genuine laboratory reports.
Jurisdiction Notice
TB-500 cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Every released batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number then resolves to the report. Specimen documents on this site are for demonstration only.
For laboratory research only. Not for human consumption. No medical claims.
